In the wake of vaccine development during the COVID-19 pandemic, the value of RNA technologies is at an all-time high. This is reflected by the number of new patent filings, particularly for mRNA vaccine technologies.
However, patenting RNA technologies at the EPO has its own unique challenges. There's a lack of specific examination guidelines and developed case law compared to more mature fields of technology, which has the potential for inconsistent examination practice and unpredictability. In addition, navigating the prior art landscape may be more demanding due to the increasing number of new applications becoming available as prior art. It's therefore important that applications are drafted carefully with a European focus from the start to avoid falling short of key patentability requirements.
In this 30-minute webinar, we’ll provide drafting tips that address the patentability pitfalls that we regularly encounter in this expanding field, to ensure the best chance of success in Europe.
We hope you can join us!